Expertise in
11
conditions

Chern-en H. Chiang

201, Sec. 2, Shih Pai Road, 
Taipei, TNQ, TW 
Expertise in
11
conditions
201, Sec. 2, Shih Pai Road, 
Taipei, TNQ, TW 

Overview

Chern-en Chiang practices practicing medicine in Taipei, Taiwan.

Chiang is highly rated in 11 conditions, according to our data. Their clinical expertise encompasses Heart Failure, Roseola, Atrial Fibrillation, Cardiac Ablation, and Aneurysm Repair.

They are actively involved in clinical research, co-authoring 217 peer reviewed articles and participating in 2 clinical trials.

Locations

201, Sec. 2, Shih Pai Road, Taipei, TNQ, Taiwan
Other Locations
Hsinchu Science Park, Hsinchu, TNQ 30076, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
View 1 Less Clinical Trial

217 Total Publications

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
Journal: The New England journal of medicine
Published: August 31, 2026

Frequently Asked Questions about Chern-en H. Chiang

Is Chern-en H. Chiang a top-rated expert for Heart Failure?

MediFind is an objective health platform that identifies experts based on real-world data. Chern-en H. Chiang is classified as an Distinguished expert for Heart Failure, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Chern-en H. Chiang participate in research or clinical trials?

Yes. Chern-en H. Chiang has published 217 articles and abstracts on conditions like Heart Failure. You can view a list of Chern-en H. Chiang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chiang's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile